Edinburgh, UK, 28th November 2017 / Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system (CNS), to develop a gene therapy for Parkinson’s disease.
Synpromics Ltd, the leader in gene control, is listed by The Scotsman as one of the top 5 leading innovative companies in life sciences in Scotland. The life science sector employs more than 37,000 people across Scotland and continues to grow internationally, expected to be worth £8bn by 2025. Alison McLintock from Leyton shares her insights into five of the most innovative life sciences companies based in Scotland. Read more...
In a recent blog by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, Synpromics is listed as one of 7 prominent players in the UK’s thriving synthetic biology sector .
Edinburgh, UK, 6th October 2017 / Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards celebration last night. Synpromics was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.
David Venables, CEO of Synpromics, will sit on the panel ‘Gene Therapy: Building the gene medicine pipeline through next generation technologies’ on the 4th October at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California.